Pharmacokinetics of the Soluble Guanylate Cyclase Activator Cinaciguat in Individuals With Hepatic Impairment

Cinaciguat is intended for use in patients with acute decompensated heart failure. The drug is eliminated predominantly via the liver and, therefore, the potential impact of hepatic impairment on cinaciguat pharmacokinetics needs to be determined. This nonrandomized, open-label, observational study...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2012-11, Vol.52 (11), p.1714-1724
Hauptverfasser:	Frey, Reiner, Scheerans, Christian, Blunck, Martin, Mück, Wolfgang, Gnoth, Mark Jean, Unger, Sigrun, Schmidt, Anja, Wensing, Georg
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Benzoates - administration & dosage Benzoates - blood Benzoates - pharmacokinetics Blood Pressure - drug effects cinaciguat Cyclic GMP - blood Female Guanylate Cyclase Heart Rate - drug effects HEK293 Cells hepatic impairment Humans Infusions, Intravenous Liver Cirrhosis - metabolism Male Middle Aged Organic Anion Transporters - metabolism pharmacodynamics pharmacokinetics Receptors, Cytoplasmic and Nuclear soluble guanylate cyclase activator Soluble Guanylyl Cyclase Solute Carrier Organic Anion Transporter Family Member 1b1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!